SEPARATION AGREEMENTSeparation Agreement • January 4th, 2023 • Brainstorm Cell Therapeutics Inc. • Biological products, (no disgnostic substances) • New York
This SEPARATION AGREEMENT (this “Agreement”) is effective as of the date on which the last Party executes this Agreement (the “Effective Date”), by and between Ralph Kern, an individual with a mailing address of 959 First Avenue, New York, NY 10022 (“Executive”), and Brainstorm Cell Therapeutics Inc., a company registered under the laws of the State of Delaware with its principal place of business at 1325 Avenue of Americas, 28th Floor New York City, New York 10019 (the “Company” and, together with Executive, the “Parties” and each, a “Party”).
AMENDMENT No. 3 TO OFFER LETTER AGREEMENTOffer Letter Agreement • January 4th, 2023 • Brainstorm Cell Therapeutics Inc. • Biological products, (no disgnostic substances)
This AMENDMENT NO. 3 TO OFFER LETTER AGREEMENT (the “Amendment”) is effective as of the date on which the last party executes this Amendment (“Amendment Effective Date”), by and between BRAINSTORM CELL THERAPEUTICS INC., a Delaware corporation with a mailing address of 1325 Avenue of Americas, 28th Floor New York, NY 10019 (the “Company”), and DR. STACY LINDBORG, an individual (the “Executive”).
